Industry News

Kadmon Holdings, Inc. today announced that the first patient has been dosed in a Phase 2 clinical trial of KD025, the Company’ s rho-associated coiled-coil kinase 2 inhibitor, for the treatment of chronic graft-versus-host disease. The randomized, open-label, 24- week study examines the safety, tolerability and activity of KD025 dosed at 200 mg once daily, 200 mg twice daily or 400 mg QD in 48 cGVHD patients in the United States. cGVHD is a common and often fatal complication..."/>
Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 in Chronic Graft-Versus Host Disease
Concert Pharmaceuticals, Inc. today announced that the Company will present a poster at the 30th Annual North American Cystic Fibrosis Conference being held October 27-29, 2016, in Orlando, Florida. Data describing the relative bioavailability of CTP-656 under fasted and fed conditions along with results from the Phase 1 multiple ascending dose study will be presented. Details on the upcoming poster presentation follow below."/>
Concert Pharmaceuticals Announces Upcoming Poster Presentation at North American Cystic Fibrosis Conference
T2 Biosystems, Inc., a company developing innovative diagnostic products to improve patient health, announced that Tom Lowery, Ph.D., chief scientific officer, today presented data on the T2 Magnetic Resonance technology for the detection of Borrelia– the bacteria that causes Lyme disease– directly from whole blood samples. The data were presented at the Diagnostic Tests for Lyme Disease Conference at the Banbury Center at Cold Spring Harbor..."/>
T2 Biosystems Presents Data on the Company’s T2MR® Technology for the Detection of the Bacteria that Causes Lyme Disease Directly from Whole Blood at Cold Spring Harbor Laboratory Conference on Diagnostic Tests for Lyme Disease
Eleven Biotherapeutics, Inc., today reported that in connection with the appointment of each of Stephen Hurly as President and Chief Executive Officer, Arthur P. DeCillis, M.D., as Chief Medical Officer, Glen MacDonald, Ph.D., as Chief Scientific Officer and Gregory P. Adams, Ph.D., as Chief Development Officer, the Company entered into employment agreements with each of Mr. Adams which provided for the grant of an inducement equity award outside the Company's 2014..."/>
Eleven Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced that it has granted stock options to Yvonne Greenstreet, the Company's newly appointed Chief Operating Officer. The compensation committee of Alnylam's board of directors approved the grant, effective as of September 19, 2016, to Dr. Greenstreet of non-qualified stock options to purchase an aggregate of 150,000 shares of Alnylam's common stock."/>
Alnylam Pharmaceuticals, Inc. Reports Inducement Grant to New Chief Operating Officer
Sarepta Therapeutics, Inc., a developer of innovative RNA-targeted therapeutics, today announced that it is offering to sell, subject to market and other conditions, up to $225 million of its common stock in an underwritten public offering. Sarepta also intends to grant the underwriters a 30- day option to purchase from it up to an additional 15% of the shares of common stock offered in the public offering. Morgan and Goldman Sachs are acting as joint..."/>
Sarepta Therapeutics Announces Proposed Public Offering of Common Stock
Analogic Corporation, enabling the world’ s medical imaging and aviation security technology, announced today that its BK Ultrasound business has created BK Finance to provide a variety of flexible financing solutions for its ultrasound product portfolio.. The BK Finance program is offered in cooperation with DLL, the world’ s leading provider of vendor finance programs. DLL has a 40- year history working with manufacturers and their distribution..."/>
Analogic Teams with DLL to Offer Financing Options to BK Ultrasound Customers
M and A Navigator: Deal pipeline –21 September
Spectrum Pharmaceuticals, Inc. concerning the Company and its officers’ possible violations of federal securities laws. The investigation concerns whether the Company misled investors regarding the FDA’ s inquiry into whether data from the Spectrum 611 and 612 Studies were clinically meaningful; and whether the FDA advised defendants in December 2012 not to submit the New Drug Application..."/>
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Spectrum Pharmaceuticals, Inc. Investors
Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, announced today that Stephen T. Wills, the Company’ s Executive Chairman and Interim Principal Executive Officer, will present at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27th at 8:30 a.m. Eastern time. The program includes a formal presentation followed by a“ fireside chat.” The conference is being held at the Sofitel New York in New York..."/>
Derma Sciences to Present at the Ladenburg Thalmann 2016 Healthcare Conference
Northwest Biotherapeutics, a U.S. biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, Chief Technical Officer, today presented an updated and more detailed analysis of the Phase I DCVax ®- Direct Trial data at the 5 th Annual SMi Cancer Vaccines Conference in London, England. DC Vax-Direct is designed to treat inoperable solid tumors."/>
NW Bio Presents Updated Data From DCVax®-Direct Phase I Trial At 5th Annual SMi Cancer Vaccines Conference in London
MRI Interventions, Inc. today announced that its ClearPoint Neuro Navigation System will be utilized at a Practical Clinic entitled "Laser Ablation Surgery: Opportunities, Indications, Technique and Outcomes" during the Congress of Neurological Surgeons taking place on September 24- 28, 2016, in San Diego, California. Both the lecture and..."/>
MRI Interventions' ClearPoint(R) Neuro-Navigation System to be Featured at the Congress of Neurological Surgeons ("CNS"), in a Hands-On Workshop Entitled, "Laser Ablation Surgery Practical Clinic"
Allergan plc will acquire US-based clinical stage biopharmaceutical company Tobira Therapeutics, Inc. for an upfront payment of USD 28.35 per share, in cash, and up to USD 49.84 per share in contingent value rights, for a total potential consideration of up to USD 1.695 bn, the company said. The boards of directors of both companies have unanimously approved the transaction. Under the terms of the merger agreement, a..."/>
Allergan to Acquire US Drugmaker Tobira Therapeutics for up to USD 1.695bn
Misonix, Inc. concerning the Company and its officers’ possible violations of federal securities laws. On September 15, 2016, the Company announced that the Audit Committee of the Company has determined that deficiencies existed in the Company's internal control over financial reporting at June 30, 2016. On this news Company shares dropped over 18%, or $1.13 per share, to close on September 15, 2016..."/>
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Misonix, Inc. Investors
UnitedHealth Group's free-standing pharmacy care services business, is adding 120 pharmacy customer service representative jobs in Costa Mesa. These new customer service positions, including bilingual customer service roles, will support the pharmacy benefit needs of OptumRx members and help deliver better health care experiences. OptumRx helps clients and more than 64 million members achieve better health outcomes and lower overall costs..."/>
OptumRx Recruiting for 120 New Customer Service Jobs in Costa Mesa
Pacira Pharmaceuticals, Inc. today announced new data regarding the benefit of EXPAREL ® for patients undergoing third molar extraction, marking the official launch of the product to the oral surgeon community. EXPAREL is a local analgesic that provides prolonged non-opioid postsurgical pain control.. As the nation battles the opioid addiction crisis, there is a particular opportunity to offer opioid alternatives to treat postsurgical pain..."/>
Pacira Pharmaceuticals Announces Official Launch of EXPAREL to the Oral Surgeon Community to Treat Pain Following Oral and Maxillofacial Procedures
Medical Facilities Corporation announced today that a cash dividend payment of Cdn $0.09375 per common share will be payable on October 17, 2016 to holders of record of common shares at the close of business on September 30, 2016. This will be the Company's 150 th consecutive dividend payment since inception. The ex-dividend date for this distribution..."/>
Medical Facilities Corporation Announces September Dividend
Immune Therapeutics, Inc., a clinical-stage pharmaceutical company focused on the commercialization and development of the first affordable non-toxic immunodulator for the treatment of inflammatory diseases, immune-related disorders, and cancer, today announces the appointment of two new members to its Medical and Clinical Advisory Board comprised of: Joseph M. Chalil, MD and Mak Jawadekar, Ph.D., join Clifford A. Selsky,..."/>
Immune Therapeutics, Inc. Announces Appointments to its Medical and Clinical Advisory Board

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology668 Articles
Consumer Discretionary610 Articles
Financials441 Articles
Industrials379 Articles
Health Care379 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at